Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > LATEST
LATEST
-
REGULATORY Japan Wants to See Positive Trends on Drug Development after Reform: Official
April 23, 2024
-
BUSINESS Takeda Inks Collab with Japan Cancer Research Foundation
April 23, 2024
-
BUSINESS Takeda, Astellas, SMBC Join Forces to Fill Vally of Death in Japan
April 23, 2024
-
BUSINESS Astellas Challenges Negative District Court Decision in Myrbetriq Patent Row
April 23, 2024
-
BUSINESS Healthcare Stakeholders Already Fret Smaller Coverage for LLPs
April 23, 2024
-
REGULATORY Japan Unveils 1,095 Off-Patent Branded Drugs Subject to New Coverage Rule
April 23, 2024
-
REGULATORY Japan Commences Project to Provide Telemedicine Services at Post Offices
April 22, 2024
-
REGULATORY MHLW Proposes Simplified Generic Delisting Scheme
April 22, 2024
-
REGULATORY Carcinogen Self-Inspection Survey Suggest 10% of Products at Risk: MHLW
April 22, 2024
-
BUSINESS Roche Diagnostics Files 2 Alzheimer’s Test Assays for β-Amyloid, Tau
April 22, 2024
-
BUSINESS Subcutaneous Entyvio Wins US FDA Nod for Crohn’s Disease: Takeda
April 22, 2024
-
BUSINESS Alecensa Nabs Adjuvant Nod for ALK-Positive Lung Cancer in US
April 22, 2024
-
BUSINESS Chugai to Commercialize Alnylam’s RNAi Hypertension Drug in Japan
April 22, 2024
-
REGULATORY More Unexpected Substances in Kobayashi’s Beni-Koji Supplements: MHLW
April 22, 2024
-
REGULATORY Japan to Discard 240 Million COVID Shots, but Says Purchase Wasn’t a Waste
April 22, 2024
-
COMMENTARY Can Japan Generic Industry Accelerate Self-Reform? MHLW Panel Debate Now in Homestretch
April 19, 2024
-
BUSINESS Renalys Aims to File Sparsentan for IgA Nephropathy in Japan in 2026
April 19, 2024
-
REGULATORY Japan Ups Efforts to Better Communicate Pricing, Regulations to Overseas: Official
April 19, 2024
-
REGULATORY MHLW Panel Sets Topics for PMD Act Amendment; Pediatrics, Drug Loss on Agenda
April 19, 2024
-
ORGANIZATION JPMA Reiterates Opposition to Off-Year Revisions towards Honebuto 2024
April 19, 2024
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…